GlassScriptPhysician profile
Mariya Bondarenko
NPI 1255925079
$4,316.45
in general payments reported to CMS, 2019-2025
30 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $920 · 2022: $521 · 2023: $774 · 2024: $911 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $479.30 | 2023-2025 | |
| Amgen INC. | $343.29 | 2024-2025 | Krystexxa |
| Kyowa Kirin, INC. | $235.23 | 2023-2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.23 | 2025 | Jardiance |
| Scilex Pharmaceuticals INC. | $230.03 | 2021-2023 | Ztlido |
| Teva Pharmaceuticals USA, INC. | $223.22 | 2024-2025 | Austedo Xr, Austedo Xr |
| Alnylam Pharmaceuticals INC. | $215.57 | 2021-2025 | Amvuttra |
| Biohaven Pharmaceuticals, INC. | $212.02 | 2021 | |
| Sanofi-Aventis U.S. LLC | $206.28 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.88 | 2021-2023 | Xifaxan |
| Abbvie INC. | $172.20 | 2021-2023 | |
| Redhill Biopharma INC. | $146.38 | 2021 | |
| Neurelis, INC. | $125.00 | 2024 | Valtoco |
| Sk Life Science, INC. | $124.10 | 2024 | Xcopri |
| Astrazeneca Pharmaceuticals LP | $120.16 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $115.75 | 2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $115.42 | 2025 | |
| Genentech USA, INC. | $106.57 | 2021 | |
| Exeltis, USA INC. | $103.35 | 2025 | Twirla, Slynd |
| Merck Sharp & Dohme LLC | $100.62 | 2023 | Verquvo |
| Jazz Pharmaceuticals INC. | $100.04 | 2022 | |
| Optinose US, INC. | $96.96 | 2024 | |
| Novo Nordisk INC | $87.03 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $81.69 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $55.86 | 2022-2023 | Seglentis |
| Biodelivery Sciences International, INC. | $36.93 | 2021 | |
| Collegium Pharmaceutical, INC. | $22.13 | 2022 | |
| Almatica Pharma LLC | $18.29 | 2022 | |
| Lilly USA, LLC | $14.30 | 2025 | Mounjaro, Zepbound |
| Arbor Pharmaceuticals, INC. | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariya Bondarenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.